<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cytokine-mobilized peripheral blood is increasingly used instead of bone marrow as the source of cells for allogeneic transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>Although cells lead to faster hematologic recovery, their effects on <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e>, relapse, and survival are less certain </plain></SENT>
<SENT sid="2" pm="."><plain>Between January 1996 and February 2000, 228 patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, or <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> were randomized to receive either bone marrow or peripheral blood allografts from HLA-matched siblings </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received <z:chebi fb="0" ids="28901">busulfan</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> as conditioning chemotherapy and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> as <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> prophylaxis </plain></SENT>
<SENT sid="4" pm="."><plain>We compared the times to neutrophil and platelet recovery, <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e>, relapse, and overall survival between the groups </plain></SENT>
<SENT sid="5" pm="."><plain>The median times to neutrophil recovery were 19 days and 23 days and the times to platelet recovery were 16 days and 22 days in the peripheral blood and bone marrow groups, respectively (P &lt;.0001 for both comparisons) </plain></SENT>
<SENT sid="6" pm="."><plain>The cumulative incidence of grades II to IV <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> 100 days after transplantation was 44% in both groups (hazard ratio, 0.99; 95% confidence interval, 0.66-1.49; P &gt;.9), and the incidence of extensive <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> at 30 months after transplantation was 40% with peripheral blood and 30% with bone marrow (hazard ratio, 1.23; 95% confidence interval, 0.78-1.96; P =.37) </plain></SENT>
<SENT sid="7" pm="."><plain>There was no statistically significant difference in the probability of relapse of the underlying disease between the groups </plain></SENT>
<SENT sid="8" pm="."><plain>The probabilities of survival at 30 months after transplantation were 68% and 60% in the peripheral blood and bone marrow groups, respectively (hazard ratio, 0.62; 95% confidence interval, 0.39-0.97; P =.04) </plain></SENT>
<SENT sid="9" pm="."><plain>In patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, and <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> undergoing allogeneic transplantation from matched siblings, the use of peripheral blood instead of bone marrow leads to faster hematologic recovery, similar risk of <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e>, and improved survival </plain></SENT>
</text></document>